Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 14 | 2016 | 341 | 1.140 |
Why?
|
| Peritoneal Neoplasms | 3 | 2015 | 28 | 0.870 |
Why?
|
| Neoplasms | 7 | 2023 | 1364 | 0.870 |
Why?
|
| General Surgery | 2 | 2023 | 212 | 0.750 |
Why?
|
| Societies, Medical | 1 | 2023 | 379 | 0.700 |
Why?
|
| Preoperative Care | 3 | 2019 | 193 | 0.630 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2018 | 40 | 0.550 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 90 | 0.540 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 1198 | 0.530 |
Why?
|
| Potassium Iodide | 1 | 2016 | 4 | 0.510 |
Why?
|
| Graves Disease | 1 | 2016 | 16 | 0.510 |
Why?
|
| Thyroidectomy | 1 | 2016 | 31 | 0.510 |
Why?
|
| Pancreatectomy | 7 | 2016 | 102 | 0.500 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 676 | 0.500 |
Why?
|
| Frailty | 1 | 2018 | 130 | 0.490 |
Why?
|
| Genes, p16 | 1 | 2015 | 6 | 0.470 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2015 | 12 | 0.470 |
Why?
|
| Antineoplastic Agents | 4 | 2015 | 663 | 0.460 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 276 | 0.450 |
Why?
|
| Hyperthermia, Induced | 2 | 2014 | 21 | 0.420 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 3 | 0.390 |
Why?
|
| Trisaccharides | 1 | 2012 | 9 | 0.390 |
Why?
|
| Cancer Vaccines | 1 | 2012 | 49 | 0.380 |
Why?
|
| Humans | 45 | 2023 | 63512 | 0.340 |
Why?
|
| Database Management Systems | 1 | 2010 | 19 | 0.330 |
Why?
|
| Carcinoma | 1 | 2009 | 123 | 0.290 |
Why?
|
| Female | 30 | 2023 | 32912 | 0.290 |
Why?
|
| Retrospective Studies | 17 | 2023 | 6670 | 0.280 |
Why?
|
| Genetic Therapy | 1 | 2015 | 791 | 0.280 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 150 | 0.280 |
Why?
|
| Artificial Intelligence | 1 | 2010 | 179 | 0.270 |
Why?
|
| Adenoma | 2 | 2007 | 70 | 0.260 |
Why?
|
| Liver Neoplasms | 2 | 2009 | 297 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 449 | 0.240 |
Why?
|
| Radiopharmaceuticals | 2 | 2021 | 190 | 0.230 |
Why?
|
| Male | 27 | 2023 | 29927 | 0.230 |
Why?
|
| Palliative Care | 1 | 2007 | 230 | 0.230 |
Why?
|
| Injections, Intralesional | 2 | 2016 | 14 | 0.220 |
Why?
|
| Hepatectomy | 2 | 2019 | 63 | 0.220 |
Why?
|
| Middle Aged | 24 | 2019 | 17641 | 0.220 |
Why?
|
| Adult | 12 | 2023 | 16837 | 0.220 |
Why?
|
| Treatment Outcome | 11 | 2016 | 5699 | 0.210 |
Why?
|
| Hyperparathyroidism | 1 | 2003 | 7 | 0.210 |
Why?
|
| Parathyroid Neoplasms | 1 | 2003 | 5 | 0.210 |
Why?
|
| Parathyroidectomy | 1 | 2003 | 7 | 0.210 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2003 | 33 | 0.200 |
Why?
|
| Catheter Ablation | 1 | 2005 | 155 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 774 | 0.200 |
Why?
|
| Intestinal Obstruction | 1 | 2023 | 53 | 0.200 |
Why?
|
| New England | 1 | 2023 | 275 | 0.200 |
Why?
|
| History, 21st Century | 1 | 2023 | 173 | 0.200 |
Why?
|
| Melanoma | 2 | 2016 | 331 | 0.200 |
Why?
|
| History, 20th Century | 1 | 2023 | 231 | 0.190 |
Why?
|
| Lung | 2 | 2023 | 956 | 0.180 |
Why?
|
| Aged | 18 | 2016 | 14469 | 0.180 |
Why?
|
| Laparoscopy | 3 | 2021 | 495 | 0.180 |
Why?
|
| Hernia, Hiatal | 1 | 2021 | 28 | 0.180 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2015 | 111 | 0.180 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 23 | 0.170 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2462 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 52 | 0.170 |
Why?
|
| Risk Assessment | 3 | 2021 | 2082 | 0.170 |
Why?
|
| Survival Rate | 7 | 2010 | 851 | 0.160 |
Why?
|
| Postoperative Complications | 4 | 2021 | 1311 | 0.160 |
Why?
|
| Lumbar Vertebrae | 1 | 2021 | 160 | 0.160 |
Why?
|
| Spinal Fusion | 1 | 2021 | 148 | 0.160 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 41 | 0.150 |
Why?
|
| Vaccination | 1 | 2021 | 364 | 0.150 |
Why?
|
| Injections, Intraperitoneal | 2 | 2015 | 47 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2005 | 1647 | 0.140 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 5471 | 0.140 |
Why?
|
| Pandemics | 1 | 2023 | 673 | 0.140 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2016 | 64 | 0.140 |
Why?
|
| Hospital Mortality | 7 | 2010 | 878 | 0.140 |
Why?
|
| Caregivers | 1 | 2021 | 272 | 0.140 |
Why?
|
| Mice, Nude | 2 | 2015 | 277 | 0.130 |
Why?
|
| Lymphoscintigraphy | 1 | 2016 | 6 | 0.130 |
Why?
|
| Adrenalectomy | 2 | 2010 | 25 | 0.130 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 349 | 0.130 |
Why?
|
| Sentinel Lymph Node | 1 | 2016 | 13 | 0.130 |
Why?
|
| Methylene Blue | 1 | 2016 | 22 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2018 | 288 | 0.130 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 41 | 0.130 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 65 | 0.130 |
Why?
|
| Coloring Agents | 1 | 2016 | 54 | 0.130 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2016 | 7 | 0.120 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 222 | 0.120 |
Why?
|
| Operative Time | 1 | 2016 | 92 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2016 | 144 | 0.120 |
Why?
|
| Glycolipids | 1 | 2016 | 44 | 0.120 |
Why?
|
| Pancreas, Exocrine | 1 | 2016 | 12 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2578 | 0.120 |
Why?
|
| Databases, Factual | 3 | 2016 | 873 | 0.120 |
Why?
|
| Pancreatitis, Chronic | 1 | 2015 | 19 | 0.120 |
Why?
|
| Diet | 1 | 2019 | 527 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 167 | 0.110 |
Why?
|
| Random Allocation | 1 | 2015 | 199 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2015 | 127 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2015 | 134 | 0.110 |
Why?
|
| Neoplasm Staging | 5 | 2010 | 510 | 0.110 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 279 | 0.110 |
Why?
|
| Hospital Information Systems | 1 | 2013 | 11 | 0.110 |
Why?
|
| United States | 11 | 2023 | 7855 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2008 | 508 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 374 | 0.100 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2012 | 3 | 0.100 |
Why?
|
| Risk Factors | 8 | 2021 | 5359 | 0.100 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2012 | 50 | 0.100 |
Why?
|
| MCF-7 Cells | 1 | 2012 | 69 | 0.100 |
Why?
|
| Apoptosis | 2 | 2015 | 1079 | 0.090 |
Why?
|
| Quality of Life | 2 | 2010 | 1230 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2012 | 182 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 412 | 0.090 |
Why?
|
| Quality of Health Care | 2 | 2021 | 517 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 168 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1471 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2013 | 268 | 0.080 |
Why?
|
| Methionine | 1 | 2010 | 55 | 0.080 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2010 | 28 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2013 | 361 | 0.080 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2010 | 16 | 0.080 |
Why?
|
| Sarcoma | 1 | 2010 | 36 | 0.080 |
Why?
|
| Patient Simulation | 1 | 2010 | 72 | 0.080 |
Why?
|
| Inpatients | 2 | 2010 | 305 | 0.080 |
Why?
|
| Infusions, Parenteral | 1 | 2009 | 22 | 0.080 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2009 | 17 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 87 | 0.080 |
Why?
|
| Mitomycin | 1 | 2009 | 26 | 0.080 |
Why?
|
| Digestive System Diseases | 1 | 2009 | 14 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 36 | 0.080 |
Why?
|
| SEER Program | 4 | 2010 | 74 | 0.080 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 31 | 0.080 |
Why?
|
| Incidence | 3 | 2021 | 1380 | 0.080 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2009 | 53 | 0.070 |
Why?
|
| Neuroendocrine Tumors | 1 | 2009 | 22 | 0.070 |
Why?
|
| Cisplatin | 1 | 2009 | 139 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2015 | 879 | 0.070 |
Why?
|
| Pancreatitis | 1 | 2009 | 97 | 0.070 |
Why?
|
| Sp1 Transcription Factor | 1 | 2008 | 21 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 279 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2010 | 346 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2016 | 60 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 346 | 0.070 |
Why?
|
| Emotions | 1 | 2010 | 223 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 46 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2009 | 268 | 0.070 |
Why?
|
| Prognosis | 4 | 2019 | 1749 | 0.070 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2010 | 44 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 1655 | 0.070 |
Why?
|
| Gastrectomy | 1 | 2007 | 40 | 0.070 |
Why?
|
| Thyroid Neoplasms | 1 | 2007 | 74 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2007 | 80 | 0.060 |
Why?
|
| Curriculum | 1 | 2010 | 600 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 598 | 0.060 |
Why?
|
| Communication | 1 | 2010 | 573 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 360 | 0.060 |
Why?
|
| Algorithms | 1 | 2010 | 1003 | 0.060 |
Why?
|
| Radiography, Interventional | 1 | 2005 | 76 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 455 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 338 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2007 | 433 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 1186 | 0.050 |
Why?
|
| Mice | 2 | 2015 | 10846 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 3770 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 125 | 0.050 |
Why?
|
| Animals | 4 | 2015 | 20666 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 89 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2010 | 809 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2003 | 129 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 2002 | 27 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2005 | 435 | 0.040 |
Why?
|
| Surgical Mesh | 1 | 2021 | 59 | 0.040 |
Why?
|
| Herniorrhaphy | 1 | 2021 | 70 | 0.040 |
Why?
|
| Esophagectomy | 1 | 2021 | 48 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 98 | 0.040 |
Why?
|
| Patient Selection | 1 | 2023 | 490 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 574 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2010 | 2574 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 644 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2021 | 152 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2009 | 137 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 980 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 394 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2007 | 254 | 0.030 |
Why?
|
| Age Distribution | 2 | 2007 | 259 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1173 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 690 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 88 | 0.030 |
Why?
|
| Comorbidity | 2 | 2010 | 1120 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 937 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 867 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2008 | 897 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 572 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2016 | 256 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 220 | 0.030 |
Why?
|
| Swine | 1 | 2014 | 380 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 136 | 0.020 |
Why?
|
| Length of Stay | 2 | 2009 | 815 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 322 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 719 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 317 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2010 | 51 | 0.020 |
Why?
|
| Cetuximab | 1 | 2010 | 8 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 229 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 66 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 42 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 149 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 146 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2010 | 102 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2009 | 56 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2009 | 32 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2010 | 219 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 418 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 309 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 422 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 238 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2007 | 35 | 0.020 |
Why?
|
| Pigmentation | 1 | 2007 | 24 | 0.020 |
Why?
|
| Canada | 1 | 2007 | 154 | 0.020 |
Why?
|
| Europe | 1 | 2007 | 195 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 731 | 0.020 |
Why?
|
| Minocycline | 1 | 2007 | 27 | 0.020 |
Why?
|
| Acne Vulgaris | 1 | 2007 | 24 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2009 | 174 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 2615 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2007 | 240 | 0.020 |
Why?
|
| Adolescent | 2 | 2007 | 6248 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 753 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 4700 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 865 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2009 | 512 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2010 | 727 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2007 | 768 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2010 | 895 | 0.010 |
Why?
|
| Decision Making | 1 | 2007 | 407 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 542 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 281 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1553 | 0.010 |
Why?
|
| Massachusetts | 1 | 2008 | 2075 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 200 | 0.010 |
Why?
|
| Hospitalization | 1 | 2007 | 1364 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1537 | 0.010 |
Why?
|